Adiponectin, non-esterified fatty acids and antiphospholipid antibodies in type II diabetes mellitus

Journal of Medical Biochemistry

Volumn 31, Issue 3, 2012, Pages 199-204

  Bećarević, Mirjana ^a,b   Seferović, Jelena ^b   Ignjatović, Svetlana ^b,c   Singh, Sandra ^b   Majkić Singh, Nada ^b,c  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

adiponectin; antiphospholipid antibodies; diabetes mellitus type II

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CARDIOLIPIN ANTIBODY; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHOLIPID ANTIBODY; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84861860611     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-012-0009-y     Document Type: Article

References (37)

1. Colwell JA. Treatment for the procoagulant state in type II diabetes. Endocrinol Metab Clin North Am 2001; 30: 1011-30. (Pubitemid 33055273)
2. Bećarević M, Andrejević S, Bonači- Nikolić B, ObradovićI, Miljić P, Majkić-Singh N. Anti-oxLDL Antibodies - Marker for Arterial Thromboses in Antiphospholipid Syndrome? Clin Lab 2005; 51: 279-83. (Pubitemid 40895127)
3. Bećarević M, Singh S, Majkić-Singh N. Oxidized LDL, anti-oxidized LDL and anti-annexin A5 antibodies in primary antiphospholipid syndrome. Clin Lab 2008; 54: 97-101. (Pubitemid 351954196)
4. Bećarević M, Andrejević S, Miljić P, Bonači-Nikolić B, Majkić-Singh N. Serum lipids and anti-oxidized LDL antibodies in primary antiphospholipid syndrome. Clin Exp Rheumatol 2007; 25: 361-6. (Pubitemid 47091011)
5. Varaala O. Autoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases. J Intern Med 2000; 247: 381-4.
6. Rand JH, Wu XX, Quin AS, Chen PP, McCrae KR, Bovill EG, Taatjes DJ. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers. Am J Pathol 2003; 163: 1193-200. (Pubitemid 37040155)
7. Gable DR, Hurel SJ, Humphries SE. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 2006; 188: 231-44. (Pubitemid 44301148)
8. Popa C, Netea MG, Van Riel PLCM, Van der Meer JWM, Stalenhoef AFH. The role of TNH-alpha in chronic inflammatory conditions, intermediary metabolism and cardiovascular risk. J Lipid Res 2007; 48: 751-62.
9. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18.
10. Lemieux I. Energy partitioning in gluteal-femoral fat: does the metabolic fate of triglycerides affect coronary heart disease risk? Arterioscler Thromb Vasc Boil 2004; 24: 795-7. (Pubitemid 38620852)
11. Lloyd EE, Gaubatz JW, Burns AR, Pownall HJ. Sustained elevations in NEFA induce cyclooxygenase-2 activity and potentiate THP-1 macrophage foam cell formation. Atherosclerosis 2007; 192: 49-55. (Pubitemid 46602306)
12. Bećarević M, Seferović S, Ignjatović S, Singh S, Majkić-Singh N. Significant association of antiphospholipid antibodies and TNF-alpha: marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications. Cytokine 2011; 55: 301-6.
13. American Heart Association: Heart and Stroke Facts. Dallas: American Heart Association, 1992.
14. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.
15. Xu A, Chan KW, Hoo RLC, et al. Testosterone selectively reduces the high molecular weight form of the adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005; 280: 18073-80. (Pubitemid 41389052)
16. Lanfranco F, Zitzman M, Simoni M, Nieschlag E. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol 2004; 500-7. (Pubitemid 38482514)
17. Nischizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734-41. (Pubitemid 34970926)
18. Urbonaviciene G, Frystyk J, Flyvbjerg A, Henneberg EW, Lindholt JS. Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease. Atheriosclerosis 2010; 210: 619-24.
19. Masumi A, Otokozawa S, Asztalos BF, et al. Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring study. Atherosclerosis 2011; 217: 543-48.
20. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose specific protein: adiponectin in obesity. Biochem Biophys Res Commun 1999; 257: 79-83. (Pubitemid 29299050)
21. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-19. (Pubitemid 32755982)
22. Higashiura K, Ura N, Ohata J, et al. Correlations of adiponectin level with insulin resistance and atherosclerosis in Japanese male populations. Clin Endocrinol 2004; 61: 753-9. (Pubitemid 40006797)
23. Chan KC, Chou HH, Wu DJ, Wu YL, Huang CN. Diabetes mellitus has an additional effect on coronary artery disease - to decrease adiponectin level. Jpn Heart 2004; 45: 921-7.
24. Tshritter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52: 239-43. (Pubitemid 36173174)
25. Valsamakis G, Chetty R, Mcternan PG, et al. Fasting serum adiponectin concentration is reduced in Indo-Asian subjects and is related to HDL cholesterol. Diabetes Obes Metabol 2003; 5: 131-5. (Pubitemid 36372506)
26. Gonzales-Sanches JL, Zabena CA, Martinez-Larrad MT, et al. An SNP in the adiponectin gene is associated with decreased serum adiponectin levels and risk for impaired glucose tolerance. Obes Res 2005; 13: 807-12.
27. Choi KM, Lee KW, Seo JA, et al. The association between plasma adiponectin, ghrelin levels and cardiovascular risk factors. Eur J Endocrinol 2004; 150: 715-18. (Pubitemid 38786543)
28. Zietz B, Herfarth H, Paul G, et al. Adiponectin represents an independent cardiovascular risk factor for predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett 2003; 545: 103-4. (Pubitemid 36694683)
29. Nakamura Y, Shimada K, Fukada D, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004; 90: 528-33. (Pubitemid 38530170)
30. Randle PJ, Garland PB, Hales CN, Newsholm EA. The glucose fatty acid cycle: its role in insulin sensitivity and metabolic disturbance of diabetes mellitus. Lancet 1963; i: 785-9.
31. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell function. Eur J Clin Invest 2002; 32: 14-23. (Pubitemid 41704996)
32. Carlsson M, Wessman Y, Almgren P, Groop L. High levels of non-esterified fatty acids are associated with increased familial risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 2000; 160: 1588-94. (Pubitemid 30353892)
33. Gillery P. Nonenzymatic post-translational modification derived products: New biomarkers of protein aging. Journal of Medical Biochemistry 2011; 30: 201-6.
34. Aslan D. Biomarkers for diabetes complications: The results of several clinical studies. Journal of Medical Biochemistry 2011; 30: 207-12.
35. Blasi C. The autoimmune origin of atherosclerosis. Atherosclerosis 2008; 201: 17-32.
36. Iwashima Y, Horio T, Suzuki Y, et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atheriosclerosis 2006; 188: 384-90. (Pubitemid 44301128)
37. Fortuno A, Rodriguez A, Gomez-Ambrosi J, Fruhbeck G, Diez J. Adipose tissue as an endocrine organ: role of leptin and adiponectin in the pathogenesis of cardiovascular diseases. J Physiol Biochem 2003, 59: 51-60. (Pubitemid 36889354)